Artrya’s A$75M Placement Hinges on October Shareholder Approval
Artrya Limited has completed the first tranche of its A$75 million placement, raising approximately A$60 million to advance its AI-driven coronary artery disease platform. Eligible shareholders can now participate in a Share Purchase Plan at the same price.
- Completion of first tranche raising A$60 million at $2.05 per share
- Second tranche of A$15 million pending shareholder approval in October
- Share Purchase Plan opens for eligible shareholders from 15 September to 3 October
- Funds to support commercialisation of Salix AI-powered coronary artery disease platform
- Placement shares issued under ASX Listing Rules 7.1 and 7.1A
Capital Raise Milestone
Artrya Limited (ASX – AYA), an Australian medical technology company specialising in AI-powered cardiac diagnostics, has successfully completed the first tranche of its two-part capital raising. The company issued 29.4 million shares at $2.05 each, securing approximately A$60 million before costs. This tranche was conducted under the ASX Listing Rules 7.1 and 7.1A, targeting professional and sophisticated investors.
Next Steps for Funding
The second tranche, aiming to raise an additional A$15 million, remains subject to shareholder approval at a general meeting scheduled for October. This approval will be pivotal in finalising the full A$75 million placement, which is earmarked to accelerate the commercialisation of Artrya’s Salix platform. Salix is an AI-powered cloud solution designed for near real-time, point-of-care assessment and management of coronary artery disease, a leading cause of mortality worldwide.
Shareholder Participation Opportunity
Alongside the placement, Artrya has launched a Share Purchase Plan (SPP) offering existing eligible shareholders the chance to acquire additional shares at the same price of $2.05. The SPP opened on 15 September and will close on 3 October 2025, with shares expected to be issued shortly thereafter. This initiative allows retail investors to participate in the company’s growth alongside institutional backers.
Strategic Implications
The capital raised will underpin Artrya’s efforts to expand regulatory and commercial activities across key international markets. By leveraging its proprietary AI technology to enhance coronary CT scan analysis, Artrya aims to improve diagnostic accuracy and efficiency for clinicians managing coronary artery disease. The successful completion of this tranche signals strong investor confidence in the company’s technology and growth trajectory.
Regulatory Compliance and Transparency
Artrya has complied with all relevant provisions of the Corporations Act and ASX Listing Rules in relation to the placement. The company issued a cleansing notice confirming there is no excluded information that would require further disclosure. This transparency is crucial in maintaining investor trust as Artrya navigates its next growth phase.
Bottom Line?
With the first tranche secured and shareholder approval pending for the second, Artrya’s next moves will be closely watched by investors eager to see how its AI technology reshapes cardiac care.
Questions in the middle?
- Will shareholder approval for the second tranche be secured without issue?
- How quickly will funds from the placement accelerate Salix platform commercialisation?
- What uptake will the Share Purchase Plan see from retail investors?
